UBS downgrades Novo Nordisk rating, citing "challenging" business conditions

Novo Nordisk faces a challenging outlook, prompting UBS to downgrade its rating to "neutral" from "buy" and slash its price target to 340 DKK from 600 DKK. This reflects persistent competition from compounded GLP-1 versions and significant market share erosion by Eli Lilly's Mounjaro, which is projected to slow Novo's H2 sales growth to 6% from 18% in H1. Despite potential tailwinds from Medicare reimbursement proposals, the firm also faces headwinds from U.S. demands for drug price cuts, contributing to its over 51% year-to-date stock decline.

Analysis

Novo Nordisk faces a significant deterioration in its operational outlook, as underscored by a UBS downgrade to "neutral" and a sharp price target reduction to 340 DKK from 600 DKK. The core of this pessimism stems from two primary factors: persistent competition from compounded GLP-1 alternatives in the U.S. and accelerating market share losses to rival Eli Lilly. UBS analysis indicates that these compounded versions are likely to remain a fixture, capping cash-pay uptake for Novo's blockbuster Wegovy in its largest market. This competitive pressure is compounded by the superior market reception of Eli Lilly's Mounjaro, which has caused demand for Novo's Ozempic to plateau early. The tangible impact is a forecasted deceleration in Novo's sales growth from 18% in the first half of the year to just 6% in the second half. While potential Medicare reimbursement for obesity drugs offers a long-term tailwind, it is counteracted by immediate political pressure to cut U.S. drug prices, creating a complex and uncertain regulatory environment. This confluence of negative catalysts has already driven the stock down over 51% year-to-date, reflecting a fundamental shift in the competitive landscape of the obesity drug market.

Key Decisions for Investors

• Given the UBS downgrade, forecasted sales deceleration to 6%, and intense competitive pressure, investors should re-evaluate long positions in Novo Nordisk as near-term headwinds appear to outweigh potential catalysts.
• Monitor prescription volume and market share data for Novo's Wegovy/Ozempic versus Eli Lilly's Mounjaro, as the analysis points to a significant and ongoing shift in physician preference and patient demand towards Eli Lilly.
• Closely track U.S. political developments regarding both drug pricing demands and potential Medicare reimbursement for GLP-1s, as these regulatory factors represent the most significant risk and opportunity for the stock's future valuation.